Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q3 2025 (September 30)10holders +4
4new positions
0sold out
$0.02avg. 13F price*
At the end of Q3 2025, 10 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, up 4 from Q2 2025. 4 opened new positions and 0 sold out. The largest holders were LMR Partners LLP ($13K), Morgan Stanley ($3K) and Clear Street Group Inc. ($2K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1K |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 50,116 shares bought and 23,236 shares sold, net +26,880 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| LMR Partners LLP | — | No change | 539,588 | $13K |
| Morgan Stanley | — | No change | 146,439 | $3K |
| Clear Street Group Inc. | — | — | 79,033 | $2K |
| Susquehanna International Group, LLP | — | New | 26,302 | $750 |
| UBS Group AG | — | New | 23,414 | $539 |
| Walleye Trading LLC | — | Reduce -64.1% | 11,436 | $268 |
| Wolverine Asset Management LLC | — | Reduce -60.8% | 1,811 | $42 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $25 |
| Bank of America Corp. | — | New | 200 | $5 |
| Toronto Dominion Bank | — | New | 200 | $5 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.